暂无分享,去创建一个
R. A. Barrio | P. G. Bolcatto | N. L. Barreiro | C. I. Ventura | T. Govezensky | M. N'unez | R. Barrio | T. Govezensky | P. Bolcatto | N. Barreiro | C. Ventura | M. N'unez | Matias Núñez | Rafael A. Barrio | Cecilia I. Ventura
[1] Selva Demiralp,et al. The Economic Case for Global Vaccinations: An Epidemiological Model with International Production Networks , 2021 .
[2] A. Rinaldo,et al. Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures , 2020, Proceedings of the National Academy of Sciences.
[3] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[4] A. Gamarnik,et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. , 2020, medRxiv.
[5] R. Barrio,et al. Detecting infected asymptomatic cases in a stochastic model for spread of Covid-19: the case of Argentina , 2020, Scientific Reports.
[6] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[7] L. Matrajt,et al. Vaccine optimization for COVID-19: who to vaccinate first? , 2020, Science Advances.
[8] E. Segal,et al. Longitudinal symptom dynamics of COVID-19 infection , 2020, Nature Communications.
[9] G. Yamey. Rich countries should tithe their vaccines , 2021, Nature.
[10] M. Keeling,et al. Efficacy of contact tracing for the containment of the 2019 novel coronavirus (COVID-19) , 2020, Journal of Epidemiology & Community Health.
[11] Christophe Fraser,et al. The Effectiveness of Contact Tracing in Emerging Epidemics , 2006, PloS one.
[12] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[13] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.
[14] C. Aschwanden. The false promise of herd immunity for COVID-19 , 2020, Nature.
[15] Jessica T Davis,et al. Estimating the effect of cooperative versus uncooperative strategies of COVID-19 vaccine allocation: a modeling study , 2020 .
[16] M. Jit,et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment , 2021, The Lancet.
[17] S. Straus,et al. The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines , 2021, The Lancet.
[18] T. Hale,et al. Oxford COVID-19 Government Response Tracker , 2020 .
[19] Tzipe Govezensky,et al. A Discrete SEIRS Model for Pandemic Periodic Infectious Diseases , 2012 .
[20] Eric J Topol,et al. Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.
[21] K. Jarrod Millman,et al. Array programming with NumPy , 2020, Nat..
[22] E. Emanuel,et al. An ethical framework for global vaccine allocation , 2020, Science.
[23] Anya Göpfert,et al. Accelerating global vaccination coverage of frontline workers and populations at risk of severe COVID-19 complications , 2021, Public Health.
[24] P. Klepac,et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.
[25] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[26] Royce J. Wilson,et al. Google COVID-19 Community Mobility Reports: Anonymization Process Description (version 1.0) , 2020, ArXiv.
[27] K. Kaski,et al. Modelling Covid-19 epidemic in Mexico, Finland and Iceland , 2020, 2007.10806.
[28] Guillermo Soberon,et al. The case of Mexico , 1992 .
[29] Andrea Cornwall,et al. What is participatory research? , 1995, Social science & medicine.
[30] J. Lessler,et al. Estimating the burden of SARS-CoV-2 in France , 2020, Science.
[31] C. Fraser,et al. Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.